SOST and chronic kidney disease: We found that this variant showed a robust negative effect on sclerostin in all cohorts; however, the genetic effect estimate was particularly large in the 4D cohort, comprising individuals with end‐stage chronic kidney disease (CKD) (Supplementary Table 5B).